email article
An oral taxane plus reduced-dose capecitabine increased the progression-free interval in metastatic breast cancer (MBC) by about 3 months, initial results from a randomized trial showed.
Patients treated with tesetaxel and capecitabine had a median progression-free survival of 9.8 months as compared with 6.9 months with capecitabine monotherapy. Two-thirds of patients in the tesetaxel arm had disease control at 24 weeks versus half of those in the placebo group, and the all-oral combination regimen led to significantly more objective responses.
The benefits were consistent across prespecified subgroups and occurred within the context of a manageable side-effect profile, Joyce O Shaughnessy, MD, of Baylor University Medical Center in Dallas, reported during the San Antonio Breast Cancer Symposium virtual meeting.
Agendia, Inc.: Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting
First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity within all clinical subtypes of breast cancer Agendia, Inc., a world leader in precision oncology for breast cancer, announced new 5-year data from the NBRST trial that will be presented in a poster spotlight discussion Thursday, December 10, 2020 from 3:30pm-4:45pm CST at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020).
The poster, entitled